Ovid Therapeutics Inc (OVID) Stock Price, Quote & News

Company Profile

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 661 7661

Fax: 646 661 4027

Website: www.ovidrx.com

Address:

441 Ninth Avenue, 14th Floor, New York, United States

swingtraderqueen Oct. 23 at 2:15 PM

$OVID all in on this $YYAI $ZOMDF $BYND

0 · Reply

swingtraderqueen Oct. 23 at 2:14 PM

$OVID

0 · Reply

venkbaskar Oct. 21 at 7:26 PM

$OVID $5 in January

0 · Reply

SannieVerraderlijk Oct. 21 at 3:25 PM

$OVID Added some

0 · Reply

lucabrix Oct. 20 at 7:35 PM

$OVID great times in front of us!

0 · Reply

Tonydarien Oct. 20 at 2:56 PM

$OVID same old crap, a different smell. Day traders playing this in a $0.35 channel. We need positive top line for OV350 to launch this to $3.00.

0 · Reply

therealcryptocowboy Oct. 19 at 12:22 AM

$OVID need help fam please sign and share! https://c.org/XbNrDf8F6r

0 · Reply

stocksmanagement Oct. 18 at 6:22 AM

$OVID Check out this article from TipRanks | Ovid Therapeutics price target raised to $5 from $3 at B. Riley | https://tipranks.onelink.me/WJho/9vnu72lg

0 · Reply

docBNM Oct. 17 at 5:01 PM

$OVID seems like the supposed good news is not impressing Mr. Mkt. How low will this POS go ??!?!?!

0 · Reply

Troopers Oct. 17 at 1:12 PM

$OVID OV329 was studied in models of neuropathic pain and inflammatory pain, and it showed great activity against pain in both models. Importantly, it didn’t show tolerance or addiction. The study was published in PNAS (link below). These would be blockbuster indications! “Efficacy of GABA aminotransferase inactivator OV329 in models of neuropathic and inflammatory pain without tolerance or addiction” https://www.pnas.org/doi/10.1073/pnas.2318833121

0 · Reply

Ovid Therapeutics Inc. - Special Call

Oct 3, 2025, 7:05 AM EDT - 22 days ago

Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds

Oct 3, 2025, 7:00 AM EDT - 22 days ago

Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile

Aug 13, 2025, 8:00 AM EDT - 2 months ago

Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results

Jul 23, 2025, 8:30 AM EDT - 3 months ago

Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference

Jun 25, 2025, 8:00 AM EDT - 4 months ago

Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

May 13, 2025, 8:00 AM EDT - 5 months ago

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

Mar 11, 2025, 8:00 AM EDT - 8 months ago

Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 8:00 AM EST - 8 months ago

Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

Feb 27, 2025, 8:00 AM EST - 8 months ago

Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Feb 5, 2025, 8:00 AM EST - 9 months ago

Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Sep 11, 2024, 8:00 AM EDT - 1 year ago

Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth

Aug 19, 2024, 11:00 AM EDT - 1 year ago

Shareholders In Ovid Therapeutics Inc Invited To Participate In Fraud Investigation With The Schall Law Firm

Aug 18, 2024, 11:00 AM EDT - 1 year ago

Ovid Therapeutics Inc Investors Encouraged To Join Fraud Investigation With Schall Law Firm

Aug 17, 2024, 11:00 AM EDT - 1 year ago

Ovid Therapeutics Inc Shareholders Eligible To Participate In Fraud Investigation With Schall Law Firm

Aug 16, 2024, 11:00 AM EDT - 1 year ago

Ovid Therapeutics Inc Investors Invited To Join In Fraud Investigation With Schall Law Firm

Aug 15, 2024, 11:00 AM EDT - 1 year ago

Ovid Therapeutics Inc Shareholders Encouraged To Join Fraud Investigation With Schall Law Firm

Aug 14, 2024, 10:30 PM EDT - 1 year ago

Ovid Therapeutics Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm

Aug 14, 2024, 1:15 AM EDT - 1 year ago

Ovid Therapeutics Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results

Aug 12, 2024, 11:55 PM EDT - 1 year ago

Ovid Therapeutics Inc Investors Invited To Join Fraud Investigation With Schall Law Firm

Aug 9, 2024, 9:15 PM EDT - 1 year ago

Investors Of Ovid Therapeutics Inc Can Participate In Fraud Investigation With The Schall Law Firm

Aug 8, 2024, 4:00 PM EDT - 1 year ago

Investors Of Ovid Therapeutics Inc Eligible To Join Fraud Investigation With The Schall Law Firm

Aug 7, 2024, 11:30 PM EDT - 1 year ago

Investors Of Ovid Therapeutics Inc Can Join Fraud Investigation With The Schall Law Firm

Aug 6, 2024, 4:00 PM EDT - 1 year ago

Ovid Therapeutics Inc Investors Can Participate In Fraud Investigation With The Schall Law Firm

Aug 2, 2024, 10:00 AM EDT - 1 year ago

OVID Investors Have Opportunity to Join Ovid Therapeutics Inc. Fraud Investigation with the Schall Law Firm

Jul 30, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics to Present at Upcoming August Investor Conferences

Jul 23, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists

Jul 1, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations

Jun 17, 2024, 8:58 AM EDT - 1 year ago

What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?

TAK

Jun 17, 2024, 6:55 AM EDT - 1 year ago

Ovid Therapeutics Reports on Takeda's Announcement of Phase 3 Topline Study Results for Soticlestat

May 14, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results

May 13, 2024, 7:00 AM EDT - 1 year ago

Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Apr 9, 2024, 10:48 AM EDT - 1 year ago

Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024

Apr 4, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Mar 8, 2024, 8:00 AM EST - 1 year ago

Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results

Feb 28, 2024, 8:00 AM EST - 1 year ago

Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

Feb 6, 2024, 8:00 AM EST - 1 year ago

Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Dec 1, 2023, 7:30 AM EST - 2 years ago

Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)

Nov 3, 2023, 8:00 AM EDT - 2 years ago

Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates

Oct 18, 2023, 8:00 AM EDT - 2 years ago

Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid's Cash Runway into 2026

Oct 10, 2023, 8:00 AM EDT - 2 years ago

Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit

Sep 26, 2023, 7:30 AM EDT - 2 years ago

Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023

Sep 20, 2023, 7:30 AM EDT - 2 years ago

Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Ovid Therapeutics to Participate in Upcoming September Investor Conferences

swingtraderqueen Oct. 23 at 2:15 PM

$OVID all in on this $YYAI $ZOMDF $BYND

0 · Reply

swingtraderqueen Oct. 23 at 2:14 PM

$OVID

0 · Reply

venkbaskar Oct. 21 at 7:26 PM

$OVID $5 in January

0 · Reply

SannieVerraderlijk Oct. 21 at 3:25 PM

$OVID Added some

0 · Reply

lucabrix Oct. 20 at 7:35 PM

$OVID great times in front of us!

0 · Reply

Tonydarien Oct. 20 at 2:56 PM

$OVID same old crap, a different smell. Day traders playing this in a $0.35 channel. We need positive top line for OV350 to launch this to $3.00.

0 · Reply

therealcryptocowboy Oct. 19 at 12:22 AM

$OVID need help fam please sign and share! https://c.org/XbNrDf8F6r

0 · Reply

stocksmanagement Oct. 18 at 6:22 AM

$OVID Check out this article from TipRanks | Ovid Therapeutics price target raised to $5 from $3 at B. Riley | https://tipranks.onelink.me/WJho/9vnu72lg

0 · Reply

docBNM Oct. 17 at 5:01 PM

$OVID seems like the supposed good news is not impressing Mr. Mkt. How low will this POS go ??!?!?!

0 · Reply

Troopers Oct. 17 at 1:12 PM

0 · Reply

Jtlo Oct. 15 at 5:07 PM

$XLO this one might go crazy. $OVID $MLTX $IOBT

0 · Reply

Eagley3k Oct. 14 at 8:28 PM

$OVID looks ready to continue upward

0 · Reply

lucabrix Oct. 14 at 7:14 PM

$OVID Back on track!

0 · Reply

CasperPuff Oct. 14 at 7:13 PM

$OVID nice. Going to $3. Then $5

0 · Reply

TJknows Oct. 14 at 3:56 AM

$OVID This guy gets it.

1 · Reply

stocksmanagement Oct. 13 at 4:55 PM

$OVID https://uk.finance.yahoo.com/news/ovid-stock-soars-39-month-142700390.html

0 · Reply

Jtlo Oct. 12 at 3:05 PM

$OVID which one should I place some money in $GANX $COYA $ATHA

4 · Reply

jarias115 Oct. 12 at 1:06 AM

$OVID let it bleed so I can get in under 1.20

1 · Reply

stocksmanagement Oct. 10 at 8:21 PM

$OVID Check out this article from TipRanks | Ovid Therapeutics price target raised to $5 from $3 at B. Riley | https://tipranks.onelink.me/WJho/1a2ind8a🔥🔥🔥

0 · Reply

ZacksResearch Oct. 10 at 5:50 PM

$OVID surges 39.2% on promising Phase I epilepsy study results! 🚀 OV329, Ovid's lead candidate, shows strong GABAergic activity, boosting inhibition by up to 53% on the APB muscle. This breakthrough could position OV329 as a best-in-class seizure treatment. See what makes this a compelling buy with Zacks Rank #2 👉 https://www.zacks.com/stock/news/2766357/ovid-stock-soars-39-in-a-month-following-upbeat-epilepsy-study-data?cid=sm-stocktwits-2-2766357-body-15657&ADID=SYND_STOCKTWITS_TWEET_2_2766357_BODY_15657

0 · Reply

ZacksResearch Oct. 10 at 4:50 PM

$OVID rockets 39% in a month 🚀 Phase I epilepsy study data showed superior efficacy for its lead candidate, OV329 — early signs pointing toward best-in-class potential. See what could drive OVID’s next move 👉 https://www.zacks.com/stock/news/2766357/ovid-stock-soars-39-in-a-month-following-upbeat-epilepsy-study-data?cid=sm-stocktwits-2-2766357-teaser-15644&ADID=SYND_STOCKTWITS_TWEET_2_2766357_TEASER_15644

0 · Reply

Thorilium Oct. 10 at 3:59 PM

$OVID $ABVE so the one thing this poster is bullish about is going red :-)))

0 · Reply

Market Cap	110.93M
Revenue (ttm)	570,000.00
Net Income (ttm)	-26.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-4,636.84%
Debt to Equity Ratio	0.00

Volume	1,429,700
Avg Vol	3,208,340
Day's Range	N/A - N/A
Shares Out	71.11M
Stochastic %K	52%
Beta	0.35
Analysts	Strong Sell
Price Target	$4.50